Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (vol 46, pg 335, 2017)

Hayashi H.; Kohno T.; Ueno H.

首页> 外文期刊>Pancreas >Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (vol 46, pg 335, 2017)

【24h】

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (vol 46, pg 335, 2017)

机译：使用针对胰腺癌的预后生物标志物评估突变的KRAS，CDKN2A，TP53和SMAD4基因的效用（Vol 46，PG 335,2017）的预后生物标志物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2017年第7期|共1页
作者
Hayashi H.; Kohno T.; Ueno H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (vol 46, pg 335, 2017) [J] . Hayashi H., Kohno T., Ueno H. Pancreas . 2017,第7期

机译：使用针对胰腺癌的预后生物标志物评估突变的KRAS，CDKN2A，TP53和SMAD4基因的效用（Vol 46，PG 335,2017）的预后生物标志物
2. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer [J] . Kotryna Kvederaviciute, Ingrida Meskinyte, Edita Meskinyte-Kausiliene, Cancers . 2017,第5期

机译：胰腺癌中的KRAS，TP53，CDKN2A，SMAD4，BRCA1和BRCA2突变
3. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer [J] . OshimaM., OkanoK., MurakiS., Annals of Surgery . 2013,第2期

机译：免疫组织化学检测的3种主要基因（CDKN2A / p16，TP53和SMAD4 / DPC4）的表达强烈预测可切除胰腺癌患者的生存
4. KRAS TP53 CDKN2A SMAD4 BRCA1 and BRCA2 Mutations in Pancreatic Cancer [O] . Jonas Cicenas, Kotryna Kvederaviciute, Ingrida Meskinyte, 2017

机译：胰腺癌中的KRASTP53CDKN2ASMAD4BRCA1和BRCA2突变
5. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients [O] . Gahee Park, Joo Kyung Park, Dae-Soon Son, 2018

机译：靶向深度测序检测胰腺癌患者循环肿瘤DNA的实用性

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (vol 46, pg 335, 2017)

著录项

相似文献

相关主题

期刊订阅